Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.
Identifieur interne : 001681 ( PubMed/Checkpoint ); précédent : 001680; suivant : 001682Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.
Auteurs : G. Durrieu [France] ; Y. Rispail ; E. Chatelut ; M. Berlan ; A. Rascol ; J L Montastruc ; P. MontastrucSource :
- Clinical neuropharmacology [ 0362-5664 ] ; 1990.
English descriptors
- KwdEn :
- Aged, Dose-Response Relationship, Drug, Epinephrine (blood), Fatty Acids, Nonesterified (blood), Female, Heart Rate (drug effects), Humans, Isoproterenol (pharmacology), Kinetics, Levodopa (therapeutic use), Lymphocytes (chemistry), Male, Middle Aged, Norepinephrine (blood), Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Radioligand Assay, Receptors, Adrenergic, beta (drug effects).
- MESH :
- chemical , blood : Epinephrine, Fatty Acids, Nonesterified, Norepinephrine.
- blood : Parkinson Disease.
- chemistry : Lymphocytes.
- drug effects : Heart Rate, Receptors, Adrenergic, beta.
- drug therapy : Parkinson Disease.
- chemical , pharmacology : Isoproterenol.
- physiopathology : Parkinson Disease.
- chemical , therapeutic use : Levodopa.
- Aged, Dose-Response Relationship, Drug, Female, Humans, Kinetics, Male, Middle Aged, Radioligand Assay.
Abstract
The beta-adrenergic sensitivity in never-treated and levodopa-treated patients with Parkinson's disease (PD) was studied through the evaluation of lymphocyte beta-adrenoceptor number ([125I]cyanopindolol binding sites) and chronotropic and metabolic (plasma nonesterified fatty acids--NEFA) responses to isoproterenol. No change was found in Bmax values or affinity constant Kd between never-treated patients, levodopa-treated patients with PD, and controls. At rest, no difference was observed in heart rate, plasma catecholamine, or NEFA levels between the three groups. Isoproterenol sensitivity (chronotropic response and plasma NEFA increase) was similar in never-treated and treated PD. The results suggest that peripheral beta-adrenergic sensitivity is unaffected either by the pathophysiological process of PD or by levodopa treatment.
PubMed: 2177376
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:2177376Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.</title><author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G" last="Durrieu">G. Durrieu</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rispail, Y" sort="Rispail, Y" uniqKey="Rispail Y" first="Y" last="Rispail">Y. Rispail</name></author><author><name sortKey="Chatelut, E" sort="Chatelut, E" uniqKey="Chatelut E" first="E" last="Chatelut">E. Chatelut</name></author><author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M" last="Berlan">M. Berlan</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Montastruc, P" sort="Montastruc, P" uniqKey="Montastruc P" first="P" last="Montastruc">P. Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2177376</idno><idno type="pmid">2177376</idno><idno type="wicri:Area/PubMed/Corpus">001811</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001811</idno><idno type="wicri:Area/PubMed/Curation">001770</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001770</idno><idno type="wicri:Area/PubMed/Checkpoint">001770</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001770</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.</title><author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G" last="Durrieu">G. Durrieu</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rispail, Y" sort="Rispail, Y" uniqKey="Rispail Y" first="Y" last="Rispail">Y. Rispail</name></author><author><name sortKey="Chatelut, E" sort="Chatelut, E" uniqKey="Chatelut E" first="E" last="Chatelut">E. Chatelut</name></author><author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M" last="Berlan">M. Berlan</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Montastruc, P" sort="Montastruc, P" uniqKey="Montastruc P" first="P" last="Montastruc">P. Montastruc</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Epinephrine (blood)</term><term>Fatty Acids, Nonesterified (blood)</term><term>Female</term><term>Heart Rate (drug effects)</term><term>Humans</term><term>Isoproterenol (pharmacology)</term><term>Kinetics</term><term>Levodopa (therapeutic use)</term><term>Lymphocytes (chemistry)</term><term>Male</term><term>Middle Aged</term><term>Norepinephrine (blood)</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Radioligand Assay</term><term>Receptors, Adrenergic, beta (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Epinephrine</term><term>Fatty Acids, Nonesterified</term><term>Norepinephrine</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Heart Rate</term><term>Receptors, Adrenergic, beta</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Isoproterenol</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Kinetics</term><term>Male</term><term>Middle Aged</term><term>Radioligand Assay</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The beta-adrenergic sensitivity in never-treated and levodopa-treated patients with Parkinson's disease (PD) was studied through the evaluation of lymphocyte beta-adrenoceptor number ([125I]cyanopindolol binding sites) and chronotropic and metabolic (plasma nonesterified fatty acids--NEFA) responses to isoproterenol. No change was found in Bmax values or affinity constant Kd between never-treated patients, levodopa-treated patients with PD, and controls. At rest, no difference was observed in heart rate, plasma catecholamine, or NEFA levels between the three groups. Isoproterenol sensitivity (chronotropic response and plasma NEFA increase) was similar in never-treated and treated PD. The results suggest that peripheral beta-adrenergic sensitivity is unaffected either by the pathophysiological process of PD or by levodopa treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2177376</PMID><DateCreated><Year>1991</Year><Month>03</Month><Day>01</Day></DateCreated><DateCompleted><Year>1991</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>1990</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.</ArticleTitle><Pagination><MedlinePgn>492-9</MedlinePgn></Pagination><Abstract><AbstractText>The beta-adrenergic sensitivity in never-treated and levodopa-treated patients with Parkinson's disease (PD) was studied through the evaluation of lymphocyte beta-adrenoceptor number ([125I]cyanopindolol binding sites) and chronotropic and metabolic (plasma nonesterified fatty acids--NEFA) responses to isoproterenol. No change was found in Bmax values or affinity constant Kd between never-treated patients, levodopa-treated patients with PD, and controls. At rest, no difference was observed in heart rate, plasma catecholamine, or NEFA levels between the three groups. Isoproterenol sensitivity (chronotropic response and plasma NEFA increase) was similar in never-treated and treated PD. The results suggest that peripheral beta-adrenergic sensitivity is unaffected either by the pathophysiological process of PD or by levodopa treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durrieu</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rispail</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chatelut</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Berlan</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>L628TT009W</RegistryNumber><NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YKH834O4BH</RegistryNumber><NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005230" MajorTopicYN="N">Fatty Acids, Nonesterified</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007545" MajorTopicYN="N">Isoproterenol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011943" MajorTopicYN="N">Receptors, Adrenergic, beta</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2177376</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M" last="Berlan">M. Berlan</name><name sortKey="Chatelut, E" sort="Chatelut, E" uniqKey="Chatelut E" first="E" last="Chatelut">E. Chatelut</name><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><name sortKey="Montastruc, P" sort="Montastruc, P" uniqKey="Montastruc P" first="P" last="Montastruc">P. Montastruc</name><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name><name sortKey="Rispail, Y" sort="Rispail, Y" uniqKey="Rispail Y" first="Y" last="Rispail">Y. Rispail</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G" last="Durrieu">G. Durrieu</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:2177376
|texte= Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:2177376" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |